More leading oncology companies have outlined their planned highlights for the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). 15 May 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now only weeks away, more drugmakers and research groups are lifting the lid on data 14 May 2024
Oncology companies including New York-based giant Pfizer (NYSE: PFE) and Japan’s Astellas Pharma (TSE: 4503) have outlined details of data they intend to presen 13 May 2024
Companies including Gilead Sciences unit Kite, as well as Boston-based Treos Bio, have outlined data they intend to present at the upcoming annual meeting of th 9 May 2024
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all—from manufacturing and supplying medical radiois 26 April 2024
US pharma giant Merck & Co raised and narrowed its forecasts for profit and sales for 2024 in presenting its first-quarter financial results. 25 April 2024
A new analysis of clinical research into selinexor suggest it could be an effective maintenance therapy for certain people with endometrial cancer. 19 July 2023
As the final sessions of the 2023 congress of the American Society of Clinical Oncology (ASCO) draw to a close, attendees will reflect on a number of significan 6 June 2023
US biotech major Gilead Sciences’ recent investments into oncology—including its $11.9 billion acquisition of Kite Pharma in 2017—have made the company one of t 6 June 2023
Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) 5 June 2023
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axica 5 June 2023
Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Onco 5 June 2023
Both AstraZeneca and Merck & Co have presented data at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) that reflects the ability of 5 June 2023
In an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO), Eli Lilly (NYSE: LLY) has revealed new data for its CD4 and C 5 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.